Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo.
Journal
Nature nanotechnology
ISSN: 1748-3395
Titre abrégé: Nat Nanotechnol
Pays: England
ID NLM: 101283273
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
11
02
2019
accepted:
27
11
2019
pubmed:
29
1
2020
medline:
24
11
2020
entrez:
29
1
2020
Statut:
ppublish
Résumé
Human epidermal growth factor receptor 2 (HER2) is overexpressed in >20% of breast cancers. Dimerization of HER2 receptors leads to the activation of downstream signals enabling the proliferation and survival of malignant phenotypes. Owing to the high expression levels of HER2, combination therapies are currently required for the treatment of HER2
Identifiants
pubmed: 31988501
doi: 10.1038/s41565-019-0626-4
pii: 10.1038/s41565-019-0626-4
pmc: PMC7147967
mid: NIHMS1544871
doi:
Substances chimiques
Antineoplastic Agents
0
Peptides
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
145-153Subventions
Organisme : NCI NIH HHS
ID : R01 CA115483
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA232845
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA198880
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB012569
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD086195
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA199668
Pays : United States
Références
Nature. 2012 Jan 18;481(7382):492-6
pubmed: 22258506
J Clin Oncol. 2018 Mar 10;36(8):808-811
pubmed: 29381433
Nat Rev Cancer. 2004 May;4(5):361-70
pubmed: 15122207
N Engl J Med. 2002 Feb 28;346(9):645-52
pubmed: 11870241
Cell. 2006 Jun 16;125(6):1137-49
pubmed: 16777603
Annu Rev Biophys. 2008;37:353-73
pubmed: 18573086
Adv Mater. 2015 Oct 28;27(40):6125-30
pubmed: 26350172
Nat Med. 2002 Nov;8(11):1270-5
pubmed: 12379846
Science. 2017 Sep 22;357(6357):
pubmed: 28935776
Nat Nanotechnol. 2015 Feb;10(2):111-9
pubmed: 25652169
Nat Rev Clin Oncol. 2010 Jul;7(7):367-80
pubmed: 20551944
Nat Clin Pract Oncol. 2007 Oct;4(10):578-90
pubmed: 17898808
Angew Chem Int Ed Engl. 2014 Jul 28;53(31):8104-7
pubmed: 24820524
Ann Oncol. 2008 Sep;19(9):1523-9
pubmed: 18441328
Acc Chem Res. 2019 Feb 19;52(2):367-378
pubmed: 30653298
Cancer Lett. 2015 Dec 28;369(2):289-97
pubmed: 26427840
ACS Nano. 2017 Apr 25;11(4):4086-4096
pubmed: 28334523
EMBO J. 2000 Jul 3;19(13):3159-67
pubmed: 10880430
Adv Mater. 2017 Apr;29(15):
pubmed: 28195446
Adv Mater. 2018 May;30(22):e1703444
pubmed: 29460400
Nat Clin Pract Oncol. 2009 Feb;6(2):93-104
pubmed: 19107109
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
ACS Appl Mater Interfaces. 2016 Jul 13;8(27):17016-22
pubmed: 27348260
Nat Rev Clin Oncol. 2016 Mar;13(3):172-84
pubmed: 26598943
Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4416s-4420s
pubmed: 16857820
EJNMMI Res. 2016 Dec;6(1):18
pubmed: 26922417
Nat Neurosci. 2002 Dec;5(12):1288-93
pubmed: 12402041
Biotechniques. 2002 Aug;33(2):294-6
pubmed: 12188179
Chem Rev. 2018 Jun 13;118(11):5359-5391
pubmed: 29693377
Nat Clin Pract Oncol. 2008 Jun;5(6):324-35
pubmed: 18364726
J Am Chem Soc. 2015 Jan 21;137(2):576-9
pubmed: 25539667
Nat Mater. 2016 Jan;15(1):13-26
pubmed: 26681596
Clin Cancer Res. 2012 Dec 15;18(24):6634-47
pubmed: 23091114
J Med Chem. 2001 Aug 2;44(16):2565-74
pubmed: 11472210
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):279-84
pubmed: 24344305
J Am Chem Soc. 2017 Nov 1;139(43):15377-15384
pubmed: 28990765
Angew Chem Int Ed Engl. 2007;46(29):5541-4
pubmed: 17579911
Angew Chem Int Ed Engl. 2018 Sep 3;57(36):11716-11721
pubmed: 29971927
Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32
pubmed: 22124364
J Am Chem Soc. 2016 Nov 30;138(47):15397-15404
pubmed: 27797504
Nat Commun. 2016 Oct 04;7:13019
pubmed: 27698471
J Am Chem Soc. 2015 Jan 21;137(2):770-5
pubmed: 25521540
Nat Commun. 2017 Jun 21;8(1):26
pubmed: 28638095
Nat Biotechnol. 2000 Feb;18(2):194-8
pubmed: 10657127